APYX

Apyx Medical Inc

Health Care · USD

APYX

Price

$3.96

-1.00%

Cap

$166M

Earnings

3/3 beat

30d Trend

-1%

APYX
Loading chart data...
0 days · % change from startPowered by Brain47
52-week range85%
0.834.5

Near 52-week highs — limited upside before resistance

Analyst consensus (6 analysts)+64% to target
1 Strong Buy3 Buy1 Hold1 Sell0 Strong Sell

Target range: $6$8 (consensus: $6.5)

Consensus: Moderate Buy

Earnings history

Q4 2025

BEAT

-0.03 vs -0.06

Q3 2025

BEAT

-0.03 vs -0.05

Q2 2025

BEAT

-0.03 vs -0.21

VolatilityLow

Key macro factors

·

Regulatory Landscape and FDA Scrutiny: Apyx Medical faces regulatory issues, including the lingering impact of an FDA warning letter, which could affect product approvals and operational stability.

·

Competition and Evolving Aesthetics Market: The surgical aesthetics market is experiencing increased competition and changing dynamics, notably the rise of GLP-1 treatments, which may influence demand for traditional aesthetic procedures.

·

Global Economic Conditions and Consumer Discretionary Spending: As demand for Apyx Medical's surgical aesthetics products is tied to consumer discretionary spending, broader global economic challenges addressed by organizations like the IMF and World Bank could impact consumer confidence and willingness to invest in elective cosmetic procedures.

Apyx Medical Corporation is an advanced energy technology medical device company focused on surgical aesthetics, developing, manufacturing, and marketing products like Renuvion and the AYON Body Contouring System for cosmetic surgery and J-Plasma for hospital surgical markets.

Next earnings:2026-05-07

QUANT SCORE

Building intelligence for this stock. Brain47 needs a few days of price data to calculate technical indicators and generate a full quant score.

Want full analysis on every stock?

Brain47 provides AI-powered research across 72,000+ instruments. Stocks, ETFs, REITs and more.

Join Brain47 — Free

Generated by Brain47 AI. Educational research only. Not financial advice. Brain47 is not authorised by the FCA to provide investment advice.

Apyx Medical Inc (APYX) — Brain47 AI Score 50/100 | Analysis